Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Lymphoid 1

Conditions

Leukemia, Lymphocytic, Chronic, B-Cell 1

Interventions

pembrolizumab 98Specimen Handling 79Magnetic Resonance Spectroscopy 70Carboplatin 59Cisplatin 57Biopsy 56Nivolumab 55Radiotherapy 48Cyclophosphamide 46Paclitaxel 44Radiation 37durvalumab 34Dexamethasone 33olaparib 31Gemcitabine 31Etoposide 29Doxorubicin 29atezolizumab 27Rituximab 26Docetaxel 26Taxes 25Ipilimumab 25Bevacizumab 25Vincristine 24Lenalidomide 23Cytarabine 23Prednisone 22Platinum 22Pemetrexed 22X-Rays 21

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Has results × duvelisib × 90 days × Clear all
NCT03534323 2026-03-23

Duvelisib and Venetoclax in Relapsed or Refractory CLL or SLL or RS

Dana-Farber Cancer Institute

Phase 1/2 Active not recruiting
55 enrolled 14 charts
LymphoidOther hematologic neoplasm

Leukemia, Lymphocytic, Chronic, B-Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡